Department of Cardiovascular Surgery, University Hospital Zürich, Rämistrasse 100, 8006 Zürich, Switzerland.
Department of Cardiology, University Hospital Zürich, Rämistrasse 100, 8006 Zürich, Switzerland.
Nat Rev Cardiol. 2015 Mar;12(3):177-83. doi: 10.1038/nrcardio.2014.210. Epub 2014 Dec 23.
Advanced age is a common contraindication for cardiac surgery, particularly in high-risk patients with comorbidities, such as pulmonary and renal impairment, associated coronary artery disease, and neurological disorders. In elderly patients with degenerative mitral regurgitation who are not eligible for conventional surgical valve repair or replacement, percutaneous valve repair is emerging as a viable alternative therapeutic option. Nonsurgical and minimally invasive therapies for degenerative mitral regurgitation are of particular value in this subset of patients, because these interventions are associated with reduced perioperative mortality, clinical improvement, and faster recovery than is possible with surgical procedures. However, given that surgery remains the gold-standard treatment and should still be considered an option regardless of a patient's age, transcatheter mitral valve repair should be performed only in candidates who will gain the most benefit from it. The balance between the risks and benefits, and the value versus the futility of procedures to treat degenerative mitral regurgitation in elderly patients should be assessed by a specialized multidisciplinary care team. In this Review, we discuss the treatment options and indications for degenerative mitral regurgitation in elderly patients.
高龄是心脏手术的常见禁忌证,尤其是在合并肺部和肾脏功能不全、相关冠状动脉疾病和神经障碍等合并症的高危患者中。对于不符合传统手术瓣膜修复或置换适应证的老年退行性二尖瓣反流患者,经皮瓣膜修复术作为一种可行的治疗选择正在兴起。对于这些患者亚群,非手术和微创治疗退行性二尖瓣反流具有特别的价值,因为与手术相比,这些介入操作与围手术期死亡率降低、临床改善和更快恢复相关。然而,鉴于手术仍然是金标准治疗方法,并且无论患者年龄大小,仍应将其视为一种选择,因此只有那些最能从中获益的患者才应接受经导管二尖瓣修复术。应由专门的多学科护理团队来评估退行性二尖瓣反流治疗的风险与获益、价值与无效之间的平衡。在本篇综述中,我们讨论了老年退行性二尖瓣反流的治疗选择和适应证。